323 reports of this reaction
0.6% of all PROCHLORPERAZINE reports
#60 most reported adverse reaction
HYPONATRAEMIA is the #60 most commonly reported adverse reaction for PROCHLORPERAZINE, manufactured by Padagis US LLC. There are 323 FDA adverse event reports linking PROCHLORPERAZINE to HYPONATRAEMIA. This represents approximately 0.6% of all 58,040 adverse event reports for this drug.
PROCHLORPERAZINE has an overall safety score of 82 out of 100. Patients taking PROCHLORPERAZINE who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is a less commonly reported adverse event for PROCHLORPERAZINE, but still significant enough to appear in the safety profile.
In addition to hyponatraemia, the following adverse reactions have been reported for PROCHLORPERAZINE:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 323 FDA reports for PROCHLORPERAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 0.6% of all adverse event reports for PROCHLORPERAZINE, making it a notable side effect.
If you experience hyponatraemia while taking PROCHLORPERAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.